THAR tharimmune.com: Nilai bisnis marang pendapatan

Tharimmune, Inc. strictly controls waste disposal and reduces its carbon footprint. The EV/Sales ratio reached a local peak, after which the company focused on developing immunotherapies to combat oncology and skin inflammation. FDA orphan drug status protected the patient base with liver pathologies, fixing the metric value at 0.00.
Rincian metrik keuangan lan pasar Tharimmune Inc (THAR)

The investment attractiveness of Tharimmune, Inc. (THAR) is based on the efficiency of antibody logistics for oncology drugs, where temperature control directly protects margins. This indicator compares the total enterprise value with annual turnover, excluding the impact of leverage to identify actual market overvaluation. Analyzing the EV/Sales multiple trajectory allows for a determination of how well the fundamental value of assets aligns with current revenue generation rates.